Biotech stocks dropped again, but four reasons indicate that waiting remains the best strategy. Attitudes of investors appear not to have turned negative yet and, therefore, biotech stocks are susceptible to more selling. The biotech sell-off, while possibly presenting trading opportunities, looks problematic for long-term investors. While an imminent collapse doesn’t look likely, biotech’s... »
